Staggered by a disaster for their Alzheimer’s drug aducanumab, Biogen today took another unsteady step back away from their big focus on the memory-wasting disease as the CEO started to talk up the diversity of its pipeline.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription